Cargando…
The Anticancer Ruthenium Compound BOLD-100 Targets Glycolysis and Generates a Metabolic Vulnerability towards Glucose Deprivation
Cellular energy metabolism is reprogrammed in cancer to fuel proliferation. In oncological therapy, treatment resistance remains an obstacle and is frequently linked to metabolic perturbations. Identifying metabolic changes as vulnerabilities opens up novel approaches for the prevention or targeting...
Autores principales: | Baier, Dina, Schoenhacker-Alte, Beatrix, Rusz, Mate, Pirker, Christine, Mohr, Thomas, Mendrina, Theresa, Kirchhofer, Dominik, Meier-Menches, Samuel M., Hohenwallner, Katharina, Schaier, Martin, Rampler, Evelyn, Koellensperger, Gunda, Heffeter, Petra, Keppler, Bernhard, Berger, Walter |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875291/ https://www.ncbi.nlm.nih.gov/pubmed/35213972 http://dx.doi.org/10.3390/pharmaceutics14020238 |
Ejemplares similares
-
The Lipid Metabolism as Target and Modulator of BOLD‐100 Anticancer Activity: Crosstalk with Histone Acetylation
por: Baier, Dina, et al.
Publicado: (2023) -
Single Spheroid Metabolomics: Optimizing Sample Preparation of Three-Dimensional Multicellular Tumor Spheroids
por: Rusz, Mate, et al.
Publicado: (2019) -
Serum-binding properties of isosteric ruthenium and osmium anticancer agents elucidated by SEC–ICP–MS
por: Klose, Matthias H. M., et al.
Publicado: (2018) -
Structure–Activity
Relationships of Triple-Action
Platinum(IV) Prodrugs with Albumin-Binding Properties and Immunomodulating
Ligands
por: Fronik, Philipp, et al.
Publicado: (2021) -
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo()
por: Heffeter, Petra, et al.
Publicado: (2013)